Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (31227)	8/4/2000 9:01:00 AM
From: carepedeum2000	Read Replies (1) \| Respond to of 57584

market watch- the numbers were pretty good except for average hourly wage hike, overall, no reason for fed to raise rates, only have ppi/cpi numbers to get through now before fed meeting, start looking for the consensus to build that the fed is done for the year, which should support the market, looks like today will be a little choppy, with a head fake or two, but i think the bulls will win the fight today, trading long today with the idea that yesterdays low "may" be the bottom for this cycle, will reconsider position at 3900-4000 as opportunity for shorting still looks very tempting there, this market is going to remain volatile, need to stay on the right side of the swings, today should swing higher, monday- sentiment could totally reverse again, next big market moving news will come from cisco earnings on tuesday anyone playing vntr here?

To: Rande Is who wrote (31227)	8/4/2000 9:18:20 AM
From: BANCHEE	Respond to of 57584

Randy You came a long way, Captain!!!!!! Congrads Banchee

To: Rande Is who wrote (31227)	8/4/2000 9:35:17 AM
From: Shroom37	Read Replies (1) \| Respond to of 57584

Congratulation Rande and Mark! Are you going to San Francisco? Shroom

To: Rande Is who wrote (31227)	8/4/2000 11:06:29 AM
From: johnsto1	Respond to of 57584

TBIO Sleeper bargain here for a limited time frame. Company Symbol Shares Range Lead Underwriter Transgenomic TBIO 4.5 million $12-$14 Chase H&Q Pharmacogenomic SNP analysis instruments The advances in genomic-related research has triggered the expansion of new lines of specialized, high throughput analysis instruments. One area, tracking the relationship between drug efficacy and genetic mutations using SNP technology, has particular promise for accelerating the pace of testing drug target effectiveness. Transgenomics makes proprietary high speed analysis instruments which detect DNA mutations. Its technology is based on single nucleotide polymorphisms (SNP) and may detect mutations without previous knowledge of their presence or location on the DNA strand. Complementing its instrument sales, the firm also sells proprietary testing supplies and consumables, representing about 25% of the business. The reception to the firms instruments appears positive. It reports the sale of almost 300 units in 20 countries. Customers include such academic, research, and commercial institutions as Harvard, Stanford, Baylor, Mayo Clinic, National Cancer Institute, National Institute of Health, SmithKline Beecham, Millennium Pharmaceuticals, Merck, Novartis, and Eli Lilly. On an overall, combined basis, revenues grew by 21.6% between ‘98-’99, reaching $23 million with a 47.5% gross margin and a 42.7% net loss. On the same combined basis, between 1Q’99 and 1Q’00 revenues grew by 32.8%, reaching $6.9 million with a 44.8% gross margin and a 50% net loss. Although competing firms in this sector are growing rapidly and amid signs of saturation, valuations have been somewhat favorable. Competitor Invitrogen recently traded in the upper half of its 52-week trading range while Affymetrix recently traded in the lower half. Some loosely related recent IPOs may also add perspective. · Sequenom was a 137.8 million deal offered on 2/1/00. Offered at $26, it closed at $79.25 for a 204.8% first day. It recently traded at $45.38, off 42.7% in the aftermarket. · Luminex was a 76.5 million deal offered on 3/30/00. Offered at $17, it closed at $22.88 for a 34.6% first day. It recently traded at $41.63, adding 81.9% in the aftermarket. This firm has promising technology, accelerating unit sales, a blue chip customer list, and continuing revenue flows from consumable testing supplies. Note: the number of shares were increased to 4.5 million from 4 million.